- Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal<figure><div><img src="https://imgproxy.divecdn.com/idsdMAHsPbXObDUtQW2qRG7uveBUVv6HCTn9NTtlDOI/g:nowe:0:0/c:1207:682/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0x…BioPharma Dive · 19d ago↗ source
- Another big premium hike on the horizonFDA's crackdown on online ketamine retailers, unprecedented health care premium hikes, and more health news from Morning RoundsSTAT · 19d ago↗ source
- Sino Biopharm hooks AstraZeneca, GSK for separate respiratory partnershipsSino Biopharmaceutical announced drug development and sales pacts with two UK pharma companies on Wednesday. One will see the Hong Kong biotech license an investigational PDE3/4 inhibitor to Astr…